Pridopidine in early-stage manifest Huntington's disease: a phase 3 trial.

Impact of pridopidine on global clinical progression (cUHDRS) In the mITT population off ADMs, pridopidine showed nominally significant benefits in maintaining cUHDRS scores compared with placebo, with the largest differences (Δ) at week 26 (Δ = 0.46, P = 0.004; placebo n = 112, pridopidine n = 95), week 39 (Δ = 0.45, P = 0.014; placebo n = 107, pridopidine n = 90) and week 52 (Δ = 0.41, P = 0.035; placebo n = 104, pridopidine n = 91) (Fig. 3a ).

also in 7,732 other papers

Although improvements at week 52 (−20.21 ms, P = 0.109) and week 78 (−22.23 ms, P = 0.104) did not reach statistical significance, the overall trend favored pridopidine.

also in 111,027 other papers

At later time points, weeks 52, 65 and 78, the treatment effect persisted as a numerical trend in favor of pridopidine.

also in 1,012 other papers

Whereas pridopidine showed a trend for slower decline, participants in the placebo group showed the expected pattern of progressive TFC decline.

also in 53,322 other papers